Cystic Fibrosis – Epidemiology – Mature Markets
Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CF for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s CF forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of CF?
- Of all people diagnosed with CF, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CF over the forecast period?
All forecast data are available on Clarivate’s Insights Platform in a tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 11 cystic fibrosis patient populations, as follows:
- Diagnosed incident cases of CF.
- Diagnosed prevalent cases of CF.
- Diagnosed prevalent cases stratified by CFTR mutation.
- Diagnosed F508del homozygous prevalent cases of CF
- Diagnosed F508del heterozygous prevalent cases of CF
- Diagnosed prevalent cases of CF negative or unknown for F508del mutation
- Diagnosed prevalent cases stratified by FEV1 status.
- Diagnosed prevalent cases of CF of FEV1
- Diagnosed of prevalent cases of CF FEV1 > 80
- Diagnosed prevalent cases of CF of FEV1 40 to 80
- Diagnosed prevalent cases stratified by airway pathogen.
- Diagnosed prevalent cases of CF with chronic pseudomonas aeruginosa
- Diagnosed prevalent cases of CF with methicillin-resistant Staphylococcus aureus
- Diagnosed drug-treated prevalent cases of CF
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Cystic Fibrosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of cystic fibrosis)
- Diagnosed incident cases
- Diagnosed prevalent cases
- Diagnosed prevalent cases stratified by CFTR mutation
- Diagnosed prevalent cases stratified by FEV1 status
- Diagnosed prevalent cases stratified by airway pathogen
- Diagnosed drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference materials
